1. Home
  2. CVKD vs POAS Comparison

CVKD vs POAS Comparison

Compare CVKD & POAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

HOLD

Current Price

$8.30

Market Cap

13.3M

Sector

Health Care

ML Signal

HOLD

POAS

Phaos Technology Holdings (Cayman) Limited Class A Ordinary Shares

N/A

Current Price

$1.69

Market Cap

13.6M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
CVKD
POAS
Founded
2022
2017
Country
United States
Singapore
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
13.3M
13.6M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
CVKD
POAS
Price
$8.30
$1.69
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$32.00
N/A
AVG Volume (30 Days)
48.5K
1.8M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.91
$0.53
52 Week High
$20.39
$7.40

Technical Indicators

Market Signals
Indicator
CVKD
POAS
Relative Strength Index (RSI) 62.07 40.03
Support Level $6.64 $0.53
Resistance Level $8.79 $3.84
Average True Range (ATR) 0.64 0.77
MACD 0.40 -0.25
Stochastic Oscillator 87.03 17.89

Price Performance

Historical Comparison
CVKD
POAS

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

About POAS Phaos Technology Holdings (Cayman) Limited Class A Ordinary Shares

Phaos Technology Holdings Cayman Ltd is an investment holding company incorporated in the Cayman Islands. Through its subsidiaries, the Company engages in the research, development, manufacturing, and commercialization of advanced optical technologies and products. Leveraging its patented microsphere technology, Phaos enhances the magnification of traditional optical microscopes, enabling visualization beyond the 200nm optical limit at a commercially viable working distance. The Company offers advanced microscopy equipment and parts, along with AI-powered software solutions that complement its hardware to deliver fully integrated microscopy systems. Its technologies serve diverse sectors, including manufacturing, biomedical, and research.

Share on Social Networks: